All In Biotech

BLA 761194 · Genzyme Corp

Nexviazyme

Avalglucosidase Alfa-Ngpt · Injection · Hydrolytic Lysosomal Glycogen-specific Enzyme

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Aug 6, 2021: To treat late-onset Pompe disease

Last checked: Nov 20, 2026Latest source record: Sep 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Aug 6, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

8

2 Phase 3, 3 recruiting

FAERS reports

998

210 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS See full prescribing information for complete boxed warning. Hypersensitivity Reactions Including Anaphylaxis Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe hypersensitivity reaction occurs, discontinue NEXVIAZYME immediately and initiate appropriate medical treatment. ( 5.1 ) Infusion-Associated Reactions (IARs) If severe IARs occur, consider immediate discontinuation and initiation of appropriate medical treatment. ( 5.2 ) Risk of Acute Cardiorespiratory Failure in Susceptible Patients Patients susceptible...

What it is approved for

From the label in effect Jun 5, 2025.

NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). NEXVIAZYME is a hydrolytic lysosomal glycogen-specific enzyme indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). ( 1 )

Mechanism: Pompe disease (also known as glycogen storage disease type II, acid maltase deficiency, and glycogenosis type II) is an inherited disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid α-glucosidase (GAA) that degrades glycogen to glucose in the lysosome. GAA deficiency results in intralysosomal accumulation of glycogen in various tissues. Avalglucosidase alfa-ngpt provides an exogenous source of GAA. The M6P on avalglucosidase alfa-ngpt mediates binding to M6P receptors on the cell surface with high affinity. After binding, it is internalized and transported into...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 15, 2023 Supplement 5 · Efficacy OrphanLetterLabel
  • Aug 6, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
  • NEXVIAZYME · AVALGLUCOSIDASE ALFA-NGPT 100MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Avalglucosidase Alfa" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug specific antibody present150
  • off label use100
  • weight increased64
  • inappropriate schedule of product administration52
  • weight decreased46
  • pyrexia39
  • fatigue36
  • dyspnoea35
  • condition aggravated32
  • illness32
  • fall28
  • headache28

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202122
2022148
2023195
2024212
2025221
2026200

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nexviazyme (Avalglucosidase Alfa-Ngpt)

2024 spending

$34.7M

Beneficiaries

53

618 claims

Per beneficiary

$655,496

$1,817.49 per unit

View as table
YearSpending
2020$0
2021$948,652
2022$15,142,060
2023$21,526,673
2024$34,741,263

Part B: Nexviazyme (Avalglucosidase Alfa-Ngpt) · HCPCS J0219

2024 spending

$73.8M

Beneficiaries

122

2,092 claims

Per beneficiary

$604,977

2024 ASP limit $76.84 per unit

View as table
YearSpending
2020$0
2021$0
2022$33,477,990
2023$67,248,349
2024$73,807,184

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.